CERCAM is an element of the prognostic signature of six differentially expressed and survival-associated genes in all of the three immune subtypes, named the High-Immunity Subtype, Medium-Immunity Subtype and Low-Immunity Subtype, in colon and rectal cancer (CERCAM, CD37, CALB2, MEOX2, RASGRP2 and PCOLCE2) identified by a multivariable COX analysis [35]. Here, RASGRP2 is linked to rectal cancer.